152 related articles for article (PubMed ID: 30427938)
21. Fighting tuberculosis by drugs targeting nonreplicating
Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
[TBL] [Abstract][Full Text] [Related]
22. Statin adjunctive therapy shortens the duration of TB treatment in mice.
Dutta NK; Bruiners N; Pinn ML; Zimmerman MD; Prideaux B; Dartois V; Gennaro ML; Karakousis PC
J Antimicrob Chemother; 2016 Jun; 71(6):1570-7. PubMed ID: 26903278
[TBL] [Abstract][Full Text] [Related]
23. Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum.
Lanoix JP; Ioerger T; Ormond A; Kaya F; Sacchettini J; Dartois V; Nuermberger E
Antimicrob Agents Chemother; 2016 Feb; 60(2):735-43. PubMed ID: 26574016
[TBL] [Abstract][Full Text] [Related]
24. Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis.
Young EF; Perkowski E; Malik S; Hayden JD; Durham PG; Zhong L; Welch JT; Braunstein MS; Hickey AJ
Pharm Res; 2016 Oct; 33(10):2495-505. PubMed ID: 27351427
[TBL] [Abstract][Full Text] [Related]
25. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.
Lee BY; Clemens DL; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
Nat Commun; 2017 Jan; 8():14183. PubMed ID: 28117835
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models.
Ahmad Z; Fraig MM; Pinn ML; Tyagi S; Nuermberger EL; Grosset JH; Karakousis PC
J Antimicrob Chemother; 2011 Jul; 66(7):1560-6. PubMed ID: 21602551
[TBL] [Abstract][Full Text] [Related]
27. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
[TBL] [Abstract][Full Text] [Related]
29. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas.
Irwin SM; Gruppo V; Brooks E; Gilliland J; Scherman M; Reichlen MJ; Leistikow R; Kramnik I; Nuermberger EL; Voskuil MI; Lenaerts AJ
Antimicrob Agents Chemother; 2014 Jul; 58(7):4026-34. PubMed ID: 24798275
[TBL] [Abstract][Full Text] [Related]
30. Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
Ammerman NC; Swanson RV; Bautista EM; Almeida DV; Saini V; Omansen TF; Guo H; Chang YS; Li SY; Tapley A; Tasneen R; Tyagi S; Betoudji F; Moodley C; Ngcobo B; Pillay L; Bester LA; Singh SD; Chaisson RE; Nuermberger E; Grosset JH
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735562
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.
Driver ER; Ryan GJ; Hoff DR; Irwin SM; Basaraba RJ; Kramnik I; Lenaerts AJ
Antimicrob Agents Chemother; 2012 Jun; 56(6):3181-95. PubMed ID: 22470120
[TBL] [Abstract][Full Text] [Related]
32. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
33. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis.
Byrne ST; Denkin SM; Zhang Y
J Antimicrob Chemother; 2007 Feb; 59(2):313-6. PubMed ID: 17185297
[TBL] [Abstract][Full Text] [Related]
34. Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice.
Ordonez AA; Pokkali S; DeMarco VP; Klunk M; Mease RC; Foss CA; Pomper MG; Jain SK
Antimicrob Agents Chemother; 2015 Jan; 59(1):642-9. PubMed ID: 25403669
[TBL] [Abstract][Full Text] [Related]
35. Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.
Chakraborty S; Rhee KY
Cold Spring Harb Perspect Med; 2015 Apr; 5(8):a021147. PubMed ID: 25877396
[TBL] [Abstract][Full Text] [Related]
36. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
[TBL] [Abstract][Full Text] [Related]
37. A review of tuberculosis: Focus on bedaquiline.
Chan B; Khadem TM; Brown J
Am J Health Syst Pharm; 2013 Nov; 70(22):1984-94. PubMed ID: 24173008
[TBL] [Abstract][Full Text] [Related]
38. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
39. Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size.
de Steenwinkel JE; ten Kate MT; de Knegt GJ; Verbrugh HA; van Belkum A; Hernandez-Pando R; Bakker-Woudenberg IA
Int J Tuberc Lung Dis; 2011 Nov; 15(11):1478-84, i. PubMed ID: 22008760
[TBL] [Abstract][Full Text] [Related]
40. Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending.
Salfinger M; Migliori GB
Eur Respir J; 2015 Feb; 45(2):317-21. PubMed ID: 25653264
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
